Dr. Harty received a new five-year grant from the NIH entitled “Mechanisms of compromised CD8 T cell responses to vaccination in malaria experienced hosts.” The award totals $3,442,760, the project started June 24, 2024 and concludes April 30, 2029.

Cancer researcher Steven Offer, PhD investigates the genetic factors that increase the risk of a toxic reaction to the cancer drug Fluorouracil (5-FU). 5-FU, used since the 1970s to treat many cancers including colorectal, stomach, breast and cervical cancer, can be toxic to certain patients. While many cancer drugs can be toxic, what sets 5-FU apart is that severe illness and death is largely preventable.

Dr. Marco Hefti received a five-year NIH R01 award entitled “A non-canonical role for tau in early human brain development” from the National Institute of Neurological Disorders and Stroke. The award totals $561,007 and the project starts May 1, 2024 and concludes February 28, 2029.